MYRIAD GENETICS INC

NASDAQ: MYGN (Myriad Genetics, Inc.)

最近更新时间: 15 Nov, 1:32PM

6.71

0.36 (5.67%)

前收盘价格 6.35
收盘价格 6.25
成交量 1,097,472
平均成交量 (3个月) 1,275,231
市值 625,464,064
预期市盈率 (P/E Forward) 54.05
价格/销量 (P/S) 0.740
股市价格/股市净资产 (P/B) 1.66
52周波幅
3.76 (-43%) — 16.83 (150%)
利润日期 3 Nov 2025
营业毛利率 -12.20%
营业利益率 (TTM) -14.80%
稀释每股收益 (EPS TTM) -1.12
季度收入增长率 (YOY) -3.10%
总债务/股东权益 (D/E MRQ) 22.36%
流动比率 (MRQ) 1.90
营业现金流 (OCF TTM) -6.40 M
杠杆自由现金流 (LFCF TTM) 18.68 M
资产报酬率 (ROA TTM) -5.26%
股东权益报酬率 (ROE TTM) -13.84%

市场趋势

短期 中期
行业 Diagnostics & Research (US) 看涨 混合的
Diagnostics & Research (全球的) 看涨 混合的
股票 Myriad Genetics, Inc. 看涨 看跌

AIStockmoo 评分

-0.5
分析师共识 1.5
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 1.0
技术振荡指标 -2.5
平均 -0.50

相关股票

股票 市值 DY P/E(TTM) P/B
MYGN 625 M - - 1.66
ICLR 13 B - 22.21 1.35
OPK 1 B - - 0.760
FLGT 927 M - - 0.820
PSNL 675 M - - 5.04
PRE 186 M - - 1.28

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

部门 Healthcare
行业 Diagnostics & Research
投资方式 Small Value
内部持股比例 2.77%
机构持股比例 104.21%

所有权

姓名 日期 持有股份
Camber Capital Management Lp 30 Jun 2025 2,000,000
52周波幅
3.76 (-43%) — 16.83 (150%)
目标价格波幅
6.50 (-3%) — 9.00 (34%)
9.00 (TD Cowen, 34.13%) 保留
8.25 (22.95%)
6.50 (Wells Fargo, -3.13%) 保留
平均值 8.00 (19.23%)
总计 1 购买, 3 保留
平均价格@调整类型 6.55
公司 日期 目标价格 调整类型 价格@调整类型
Piper Sandler 11 Nov 2025 8.50 (26.68%) 购买 6.68
Wells Fargo 05 Nov 2025 6.50 (-3.13%) 保留 6.58
TD Cowen 04 Nov 2025 9.00 (34.13%) 保留 6.46
UBS 04 Nov 2025 8.00 (19.23%) 保留 6.46

该时间范围内无数据。

日期 类型 细节
11 Nov 2025 公告 Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
10 Nov 2025 公告 Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
06 Nov 2025 公告 Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
03 Nov 2025 公告 Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
31 Oct 2025 公告 New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
27 Oct 2025 公告 Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
14 Oct 2025 公告 Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
08 Oct 2025 公告 Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
23 Sep 2025 公告 Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
23 Sep 2025 公告 Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
04 Sep 2025 公告 Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
03 Sep 2025 公告 New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
27 Aug 2025 公告 Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票